Enliven Therapeutics Inc
Enliven Therapeutics Inc (ELVN) Implied Volatility Current
ELVN's 30 day implied volatility is 58.84%, with an IV Rank of 12.70%. This is a low IV Rank versus the past year, meaning Enliven Therapeutics Inc options are relatively cheap and currently favor buyers. ELVN's 30 day historical volatility sits at 56.89%, which means implied volatility is running 1.95 points above historical volatility, as of Nov 20, 2026.
Read more
Tracking ELVN implied volatility helps you spot when Enliven Therapeutics Inc options are historically cheap or expensive, and where the best trades are hiding. When ELVN IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor ELVN implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking ELVN IV rank helps you see whether ELVN's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Implied Volatility
IV is subdued. Premiums are cheap, favoring buyers.
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →